Finance

Lists
LABB:BMV
Genomma Lab Internacional SAB de CV
MX$15.17
+1.74%
(+0.26) 1D
Oct 30, 2:00:00 PM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for LABB...
Open
MX$14.60
High
MX$15.19
Low
MX$14.60
Mkt. cap
15.13B
Avg. vol.
4.34M
Volume
3.64M
Dividend
4.94%
Quarterly dividend
MX$0.19
Ex-dividend date
Sep 29, 2026
P/E ratio
8.66
52-wk high
MX$19.48
52-wk low
MX$12.22
EPS
MX$1.75
Shares outstanding
1.00B
No. of employees
2K
Open
MX$14.60
High
MX$15.19
Low
MX$14.60
Mkt. cap
15.13B
Avg. vol.
4.34M
Volume
3.64M
Dividend
4.94%
Quarterly dividend
MX$0.19
Ex-dividend date
Sep 29, 2026
P/E ratio
8.66
52-wk high
MX$19.48
52-wk low
MX$12.22
EPS
MX$1.75
Shares outstanding
1.00B
No. of employees
2K
News stories
From web sources and news partners
Profile
Genomma Lab Internacional or simply Genomma Lab is a Mexican company, founded in 1996, dedicated to the commercialization of OTC medications and dermocosmetic products. It is part of the Índice de Precios y Cotizaciones, the main stock index of the Mexican Stock Exchange. It is one of the leading pharmaceutical companies in the country. Genomma Lab Internacional, led by its owner Rodrigo Alonso Herrera Aspra, recorded net sales of 9,799.7 million Mexican pesos, equivalent to 756.0 million USD in 2012, achieving a 21.6% growth compared to 2011. Currently, Genomma Lab operates in 15 countries outside Mexico and has achieved success by replicating its business model. Wikipedia
About Genomma Lab Internacional SAB de CV
CEOJorge Luis Brake Valderrama
Employees1.8K
Founded1996
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in MXN
Loading Previous Earnings...
Revenue
Net income
All values in MXN
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
4.02B
4.19B
4.40B
4.50B
Cost of goods sold
1.57B
1.53B
1.56B
1.74B
Cost of revenue
1.57B
1.53B
1.56B
1.74B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.59B
1.78B
1.97B
1.91B
Operating expense
1.64B
1.78B
1.96B
1.90B
Total operating expenses
3.21B
3.32B
3.52B
3.63B
Operating income
805.60M
874.42M
877.20M
863.65M
Other non operating income
-62.38M
-107.62M
-100.66M
-103.14M
EBT including unusual items
568.19M
644.10M
534.73M
699.32M
EBT excluding unusual items
573.06M
644.10M
534.73M
699.32M
Income tax expense
241.94M
149.46M
160.24M
184.39M
Effective tax rate
42.58%
23.20%
29.97%
26.37%
Other operating expenses
55.69M
-1.44M
-4.17M
-7.39M
Net income
326.25M
494.65M
374.49M
514.93M
Net profit margin
8.12%
11.80%
8.52%
11.45%
Earnings per share
0.32
0.49
0.37
0.51
Interest and investment income
23.01M
35.27M
28.54M
27.92M
Interest expense
-190.68M
-177.79M
-176.65M
-130.17M
Net interest expenses
-167.67M
-142.52M
-148.12M
-102.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
900.41M
965.13M
967.58M
953.46M
Gain or loss from assets sale
2.23M
-
-1.19M
-795.00K
Upcoming events
AI content may include mistakes. Learn more
Google apps